Cargando…

1236. Baseline liver stiffness and alanine transaminase predicts reduction in liver stiffness in people with chronic hepatitis B on tenofovir alafenamide

BACKGROUND: Globally, 296 million people are infected with chronic hepatitis B (CHB) and at risk for cirrhosis and hepatocellular carcinoma. Suppressive therapy with a nucleos(t)ide analogue (NUC) such as tenofovir alafenamide (TAF) reduces risk of cirrhosis and cancer. Transient elastography measur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Lydia, George, Nivya, Price, Angie, Kottilil, Shyam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752225/ http://dx.doi.org/10.1093/ofid/ofac492.1068

Ejemplares similares

Liver Stiffness Measurement can Predict Liver Inflammation in Chronic Hepatitis B Patients with Normal Alanine Transaminase
por: Huang, Ling-Ling, et al.
Publicado: (2023)

Diagnostic accuracy of liver stiffness measurement in chronic hepatitis B patients with normal or mildly elevated alanine transaminase levels
por: Li, Qiang, et al.
Publicado: (2018)

Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial
por: Wang, Lu, et al.
Publicado: (2021)

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
por: Cheng, Chih-Hsien, et al.
Publicado: (2023)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
por: Squillace, Nicola, et al.
Publicado: (2020)

Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen
por: Darnell, Julia, et al.
Publicado: (2021)

Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver
por: TOMIZAWA, MINORU, et al.
Publicado: (2014)

Effectiveness of Tenofovir Alafenamide in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA
por: Gao, Wen-Kang, et al.
Publicado: (2022)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

The Association between Fruit and Vegetable Intake and Liver Enzymes (Aspartate and Alanine Transaminases) in Tehran, Iran
por: Mollahosseini, Mehdi, et al.
Publicado: (2017)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Entecavir‐induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide
por: Lim, I. Vern, et al.
Publicado: (2023)

Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations
por: Li, Xue, et al.
Publicado: (2021)

Baseline aspartate aminotransferase/alanine transaminase ratio is associated with 3-year mortality in peritoneal dialysis patients
por: Liao, Ruoxi, et al.
Publicado: (2022)

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023)

Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids
por: Martino, Michael R., et al.
Publicado: (2022)

Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids
por: Martino, Michael R., et al.
Publicado: (2022)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity
por: Walti, Laura N, et al.
Publicado: (2018)

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
por: Huhn, Gregory D, et al.
Publicado: (2019)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization
por: Brunet, Laurence, et al.
Publicado: (2021)

A Rise in Aspartate Transaminase and Alanine Transaminase Associated With Ondansetron Administration in a Pregnant Female
por: Couse, Michael, et al.
Publicado: (2020)

Portal Hypertension and a Stiff Liver
por: D'Alitto, Felicia, et al.
Publicado: (2018)

Effect of illness uncertainty on alanine transaminase levels and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease
por: Ozawa, Naoki, et al.
Publicado: (2022)

Spleen Stiffness Is Superior to Liver Stiffness for Predicting Esophageal Varices in Chronic Liver Disease: A Meta-Analysis
por: Ma, Xiaowen, et al.
Publicado: (2016)

Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
por: Dickson, Sean, et al.
Publicado: (2022)

The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques
por: Daly, Michele B., et al.
Publicado: (2020)

Tenofovir alafenamide nephrotoxicity: a case report and literature review
por: Ueaphongsukkit, Thornthun, et al.
Publicado: (2021)

Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide
por: Ito, Soichiro, et al.
Publicado: (2021)

Real-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey
por: Balcı, Umay, et al.
Publicado: (2023)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
por: Li, Juan, et al.
Publicado: (2021)

Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B
por: Fung, James, et al.
Publicado: (2010)

Liver stiffness and arterial stiffness/abnormal central hemodynamics in the early stage of heart failure
por: Iwasaki, Yoichi, et al.
Publicado: (2018)

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia
por: Taramasso, Lucia, et al.
Publicado: (2019)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate
por: Hermansson, Linn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l9cbu1hb0dhhhlcc5s3p1soqj7